A retrospective evaluation of geriatric patients with gastric cancer receiving systemic chemotherapy.

TATLI A. M., Urakci Z., TAŞTEKİN D., Koca D., Goksu S., Uyeturk U., ...Daha Fazla

Journal of cancer research and therapeutics, cilt.16, sa.Supplement, 2020 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 16 Sayı: Supplement
  • Basım Tarihi: 2020
  • Doi Numarası: 10.4103/jcrt.jcrt_563_18
  • Dergi Adı: Journal of cancer research and therapeutics
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, CAB Abstracts, CINAHL, EMBASE, MEDLINE, Veterinary Science Database, Directory of Open Access Journals
  • Anahtar Kelimeler: Geriatric patients, metastatic gastric cancer, systemic chemotherapy, ELDERLY-PATIENTS, 1ST-LINE CHEMOTHERAPY, POOLED ANALYSIS, ESOPHAGOGASTRIC CANCER, FOLFOX-4 REGIMEN, YOUNGER PATIENTS, SUPPORTIVE CARE, PHASE-II, OXALIPLATIN, PLUS
  • Akdeniz Üniversitesi Adresli: Evet

Özet

Background: The most common age at which gastric cancer is diagnosed is 70 years, and the majority of patients diagnosed are at the metastatic stage. However, although gastric cancer is a geriatric disease, there is no suggestion to discriminate treatment for the general geriatric patient population. Here, we evaluated patients receiving palliative chemotherapy for gastric cancer owing to advanced age. Patients and Methods: Multicenter data of geriatric patients receiving palliative chemotherapy because of metastatic gastric cancer were retrospectively reviewed. Results: In total, 262 geriatric patients with gastric cancer were included in the study. Of these, 167 patients, including 134 (51.8%) patients with metastasis at diagnosis and 33 patients with relapse after surgery, were evaluated for palliative therapy. Chemotherapy was started in 87 (52.1%) of 167 patients. The overall median survival of the patients receiving chemotherapy was 9.3 months. There was no difference in overall survival (OS) between patients aged >70 and <70 years. However, a significant difference was detected in OS of patients depending on their Eastern Cooperative Oncology Group (ECOG) performance status (PS) before treatment; survival was 15 months in the group with PS 0-1 and 7 months in the group with PS 2. Conclusion: Advanced age chemotherapy receiving rates in patients with metastatic gastric cancer is decreasing. Survival is not associated with age, but pretreatment ECOG PS is important. Therefore, ECOG PS and comorbidities should be evaluated in detail, and combination therapies could contribute to patient survival.